Bangalore, May 6, 2009: Novotech, an Australia-based clinical research company, has entered into a strategic venture with ETI Klinical, a $600 million Indian multinational.
 
The joint venture designed to service the growing demand for global clinical research in the region will operate across India and offer full clinical and data management services. 

Novotech CEO Mr Alek Safarian said the joint venture will leverage the huge opportunities in the growing Indian clinical research sector and drive more global studies to the country.

The two companies are said to have extensive experience managing FDA clinical research and will collaborate to service both regional and international pharma and biotech firms.
 
Karle Group CEO Mr Mahendra Karle said, " with the joint venture, clients could access our extensive reach across India which included Memorandum of Understanding with 92 prequalified sites with proven recruitment capability and compliance, providing access to over five million patients and 13,000 beds."
 
Therapeutic areas include oncology, gastroenterology, urology, nephrology, ophthalmology, cardiology, diabetology, dermatology, orthopedics, postoperative pain, neurology, otorhinolaryngology, infectious diseases, respiratory diseases, endocrinology, psychiatry, geriatrics, hematology, metabolic disorders devices and vaccines.
 
The joint venture data management services include Oracle Clinical and SAS, and Novotech's Clintrial giving maximum flexibility to clients.

Mr Safarian also said that ETI offers an exceptional mix of high-quality clinical research services, real-time data acquisition and personalized communication processes to manage a clinical trial from initial planning to approval, on time and on budget. “We share a similar business culture and approach to high-quality and time critical clinical trials and research, serving the pharmaceutical, biotechnology, and medical device industries,” he added.